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Abstract
Background: End-stage renal disease is associated with premature ageing of the T cell immune system but inter-
individual variation is substantial. The hypothesis was tested that advanced immunological T cell ageing assessed
by peripheral T cell differentiation increases the long-term mortality risk after renal transplantation.
Results: Circulating T cells of 211 recipients of a kidney from a living donor were analyzed before and in the first
year after transplantation. The number of CD31-positive naive T cells (as a marker for recent thymic emigrants) and
the differentiation status of the memory T cells was assessed. Thirty recipients died during follow-up of at least 5
years. Absolute numbers of naive CD4+ (living:258 cells/μl vs. deceased:101 cells/μl, p < 0.001) and naive CD8+ T
cells (living:97 cells/μl vs. deceased:37 cells/μl, p < 0.001) were significantly lower in the deceased group prior to
transplantation. In a multivariate proportional hazard analysis the number of naive CD4+ T cells remained associated
with all-cause mortality (HR 0.98, CI 0.98–0.99, p < 0.001). The low number of naive T cells in the deceased patient
group was primarily caused by a decrease in recent thymic emigrants (i.e. less CD31+ naive T cells) indicating a
lowered thymus function. In addition, the physiological age-related compensatory increase in CD31− naïve T cells
was not observed. Within the first year after transplantation, the number and characteristics of naive T cells
remained stable.
Conclusions: A severe reduction in circulating naïve T cells because of a decrease in recent thymic emigrants is
highly associated with all-cause mortality after renal transplantation.
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Background
Progressive loss of renal function leading to end-stage
renal disease (ESRD) is associated with premature ageing
of the T-cell system. The pro-inflammatory environment
resulting from loss of renal function [1] is marked by a
lower thymic output, increased T-cell differentiation,
telomere shortening and skewing of the T cell receptor
(TCR) repertoire [2–4].
The changes in the peripheral T-cell compartment of
ESRD patients resemble the physiological changes in the
immune system of healthy elderly individuals with the
immunological age of ESRD patients on average being
increased by 15–20 years compared to their chrono-
logical T-cell age [4–6].
One of the most consistent and prominent features of
ESRD-related premature aging is a lowered thymic output.
This is characterized by a decreased number in newly
formed naive T cells (i.e. recent thymic emigrants (RTE))
in the circulation. These RTE can either be recognized by
the presence of T cell receptor excision circles (circular
DNA remnants of the TCR gene rearrangement during
thymic maturation) or CD31 expression on naïve CD4 T
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cells, and close correlation exists between both assays in
healthy controls and ESRD patients [4, 7]. As the number
of differentiated memory T cells increases with age, both
mechanisms together reduce the percentage of naive T
cells in the circulation to a relatively high extent [4, 8, 9].
Furthermore, the increased proliferation and differenti-
ation reduces the T-cell telomere length and increases
skewing of the TCR repertoire [2, 3].
The driving force behind ESRD-related premature age-
ing is believed to be the pro-inflammatory environment
that arises with retention of uremic waste products,
which leads to increased oxidative stress and inflamma-
tion [1, 6, 10]. The prematurely aged T cell system of
ESRD patients is associated with a reduced vaccination
response [11–14] and an increased infection susceptibil-
ity [15]. After renal transplantation (RT), increased num-
bers of highly differentiated T cells are associated with a
decreased risk for early acute rejection [16].
Currently, it is not known whether parameters of a
prematurely aged T-cell system in ESRD patients are as-
sociated with long term survival. In this study, we inves-
tigated the association between thymic output measured
by CD31 positive naïve CD4 T cells and T-cell differen-
tiation status in recipients prior to renal transplantation
with all-cause mortality at follow-up.
Results
Recipients characteristics and all-cause mortality
Recipients characteristics are shown in Table 1. The me-
dian patient age was 57 years and the majority of the recipi-
ents (91%) underwent a renal transplantation for the first
time. Thirty recipients (median age 63 year, range 26–78)
deceased at a median of 40months after transplantation
(range 6–74months). The percentage of patients receiving
high dose steroids and/or T cell depleting therapy for acute
rejection was not significantly different between the living
and deceased recipient group (data not shown).
Pre-transplant T cell ageing parameters and survival
The average number of different T cell subsets is shown
in Table 2.
The deceased recipient group had a significantly
lower total number of circulating CD4+ T cells as a re-
sult of decreased numbers of naïve CD4+ (Fig. 1A) and
central-memory T cells. Also within the CD8+ T cell
population the naïve T cells (Fig. 1A) were significantly
decreased, but this was accompanied by an increase in
the cell count of total and more differentiated subpop-
ulations of memory T cells (effector memory and
Temra subpopulations). As a result, the total number
of CD8+ T cells was similar between the living and de-
ceased group of recipients. Cell counts of naïve CD4+
and CD8+ T cells were significantly correlated (Fig. 1B,
Rs = 0.56, p < 0.001).
The number of naïve T cells showed a progressive de-
creases with age in both healthy individuals and ESRD
patients. Confirming data of a previous publication [4],
these numbers are on average significantly lowered at all
decades in the ESRD patient group leading to a bio-
logical age difference of 20 years (Fig. 2). However, at
every decade the average number of naïve CD4+ and
CD8+ T cells was lower in the deceased recipient group
compared with the living recipient group.
Multivariate proportional hazard logistic regression ana-
lysis (Table 4) confirmed that independent of age, a lower
number of either CD4+ (HR 0.99, 95% CI 0.98–0.99, p <
0.0001) or CD8+ naïve T cells (HR 0.98, 95% CI 0.96–0.99,
p < 0.001) was significantly associated with all-cause mortal-
ity. When combining both CD4+ and CD8+ naïve T cell
numbers in the model, only the number of naïve CD4+ T
cells remained significantly associated with all-cause mor-
tality at follow-up (HR 0.99, 95% CI 0.98–0.99, p < 0.001).
The interaction term for CD4+ and CD8+ naïve T cell was
not statistically significant (not shown). As expected, similar
Table 1 Clinical and demographical characteristics of renal
allograft recipients (n = 211) prior to transplantation
Age in years, median (range) 57 (19–79)
Male/female 62–38%
Follow-up time in months, median (range) 74 (0–97)
Living kidney donor, n (%) 211 (100%)
Previous kidney transplant, n (%) 19 (9.0%)
Pre-emptive transplantation, n (%) 91 (43.1%)
Anti-rejection therapy 39 (18.4%)
T cell depleting therapy for rejection 18 (8.5%)
Cardiovascular disease prior to transplantation, n (%) 53 (25.1%)
Distribution of underlying kidney disease
Nephrosclerosis/hypertension 22.7%
Primary glomerulopathies 13.7%
Diabetes mellitus 19.9%
Urinary tract infections/ stones 2.8%
Reflux nephropathy 4.7%
Polycystic kidney disease 19.0%
Other 11.8%
Unknown 5.2%
CMV seropositive* 59%
Recipients deceased during follow-up 30
Cause of death
cardiovascular disease 20.0%
infection 26.7%
cancer 26.7%
other 3.3%
unknown 23.3%
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results were obtained using CD31pos naïve T cells instead
of total naïve T cell as a variable in the logistic regression
analysis (data not shown).
A positive CMV serostatus is an independent factor as-
sociated with a (modest) decreased number of circulating
naïve T cells in ESRD patients [17]. This effect was also
observed in the current cohort of patients, but independ-
ent of CMV serostatus the group alive at follow up had al-
most twice as much naïve T cells (and CD31pos naïve T
cells) as the deceased group (Additional file 1: Table S1).
Uni- and multivariate statistical analysis also did not show
a significant relation between a CMV positive serostatus
and mortality after transplantation (Tables 3 and 4).
Naive T cells and the CD4/CD8 ratio
Several studies have shown that an inverted CD4/CD8
T-cell ratio is associated with immunological ageing and
associated with poor survival [18, 19]. An important
contributor to this inverted ratio is CMV-seropositivity
[20, 21]. In our patient group, the CD4/CD8 T-cell ratio
was highly associated with all-cause mortality (Tables 2,
3 and 4), primarily as a consequence of a decreased
CD4+ T cell count in the deceased recipient group com-
pared to the living recipient group. This effect could not
be contributed to the influence of CMV-seropositivity as
this was equally distributed between both groups
(deceased 66.7% vs living 57.8%, p = 0.6). In fact, CMV-
seropositive recipients on average showed a significantly
decreased CD4/CD8 T-cell ratio (CMV+ vs. CMV− re-
cipients: 1.85 vs 2.91, p < 0.0001). This is because CMV
infection leads to a substantial and persisting increase in
numbers of circulating CD8+ memory T cells [22]. Thus,
the decrease in CD4/CD8 T-cell ratio in the deceased re-
cipients group was observed independently of CMV-
serostatus (data not shown).
CD31 expression on naïve T cells and survival
Expression of CD31 on naïve CD4 T cells can be used as a
marker for recent thymic emigrants both in healthy indi-
viduals and ESRD patients and correlates very closely with
results obtained by assaying the T cell receptor excision
content [4, 23, 24]. Numbers of CD31+ and CD31− naïve
CD4+ T cells were significantly lower in the deceased re-
cipient group compared to the living recipient group
(Table 2). They remained significantly associated with all-
cause death including clinical parameters such as age as a
variable in the proportional hazard regression analysis
(CD31+; HR 0.99, 95% CI 0.98–0.99, p < 0.001, CD31−; HR
0.98, 95% CI 0.97–0.99, p = 0.002).
Similar to healthy controls (n = 239), the number of
CD4+ CD31+ naïve T cells in the living recipient group
declined with age while the number of CD31− naïve T
Table 2 Immunological T cell parameters of renal allograft recipients prior to transplantation
Alive (n = 181)* Deceased (n = 30)* p-value
Total CD4 T cells 720 (418)** 404 (203) 0.001
Naive CD4 T cells 207 (233) 94 (78) < 0.001
Naïve CD4 CD31pos T cells 119 (156) 59 (59) < 0.001
Naive CD4 CD31neg T cells 66 (84) 35 (35) < 0.001
Memory CD4 T cells 471 (273) 321 (205) 0.018
Central memory CD4 T cells 289 (223) 169 (147) 0.004
Effector memory CD4 T cells 155 (124) 117 (153) 0.4
Temra CD4 T cells 10 (17) 7 (11) 0.1
CD28null memory CD4 T cells 16 (53) 25 (69) 0.4
Total CD8 T cells 356 (231) 381 (565) 0.3
Naïve CD8 T cells 67 (91) 27 (35) < 0.001
Naïve CD8 CD31pos T cells 64 (89) 26 (30) < 0.001
Naive CD8 CD31neg T cells 2 (2) 1 (3) 0.6
Memory CD8 T cells 256 (208) 299 (571) 0.039
Central memory CD8 T cells 16 (21) 14 (15) 0.7
Effector memory CD8 T cells 109 (94) 125 (214) 0.2
Temra CD8 97 (153) 149 (340) 0.2
CD28null memory CD8 T cells 119 (172) 172 (399) 0.1
CD4/CD8 T cell ratio 2.0 (1.6) 1.2 (1.3) 0.008
CMV seropositive*** 57.8% 66.7% 0.6
*Recipients alive and deceased at time of follow-up, **cell numbers are expressed in cells/μL in medians with interquartile range between parenthesis,
***percentage of recipients with detectable serum anti-cytomegalovirus antibodies
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cells increased and (partly) compensated for this decline
(Fig. 2). From the age of 70 the average number of
CD31+ and CD31− contributed roughly equally to the
composition of the circulating naïve CD4+ T cells.
In contrast, in the deceased recipient group this age-
dependent dynamics was not observed and the number
of CD31+ and CD31− naïve T cells were low in all age
decades (Fig. 2).
The number of naïve CD8+T cells decreased sharply
with age both in healthy individuals and the living recipi-
ent group. In contrast to the CD4+ naïve T cells, virtually
all naïve CD8+ T cells express CD31+ (see Table 2) which
is a known phenomenon and limits its use as a marker for
recent thymic emigrants for CD8+ T cells [25].
Numbers of naïve CD4+ and CD8+ T cells did not cor-
relate with any of the clinical and demographical charac-
teristics as shown in Table 1, except for age.
Dynamics of naïve T cell numbers during the first year
after transplantation
In both the deceased and living recipient group the num-
bers of naïve CD4 and CD8 T cells remained stable during
the first year after transplantation (Fig. 3). Also, longitu-
dinal follow-up during the first year after transplantation
Fig. 1 Naïve T cells in relation to recipient survival after transplantation. Recipient’s numbers of naïve CD4+ and CD8+ T cells at the time of kidney
transplantation divided in the recipients alive and deceased at time of follow-up (a). In the lower graph the correlation (Rs, Spearman rank
correlation coefficient) between naïve CD4+ and CD8+ T cells numbers is shown (b)
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did not show significant changes in the number of CD31+
and CD31− CD4+ naïve T cells in both the deceased and
living recipient group (Fig. 3).
Discussion
In this prospective study the hypothesis was tested that
the degree of premature immunological aging at the
time of renal transplantation is associated with long-
term all-cause mortality thereafter. Of all immunological
parameters tested, the number of circulating naïve T
cells was significantly associated with all-cause mortality
at a follow-up of 5–7 years after transplantation. In par-
ticular, the number of CD31+ CD4+ naïve T cells was
substantially lower in every age group in the deceased
recipient group, without a compensatory increase in
CD31− CD4+ naïve T cells.
Fig. 2 Total number of naïve T cells and CD31 positive and negative CD4+ naïve T cells in relation to age. Total naïve CD4+, CD31 positive
(CD31+) and CD31 negative (CD31−) naive CD4+ T cells and total naïve CD8+ T cells are shown for renal transplant recipients (n = 211) and
healthy controls (n = 239). The cross-sectional data are represented in means with standard error of the mean for healthy controls (black dots),
recipients alive (green dots) and deceased recipients at the time of follow-up (red dots). Age is shown in decades on the X-axis. Dashed
interconnecting lines are added to facilitate interpretation of the graph
Table 3 Univariate Cox regression analysis for outcome death after transplantation
HR 95% CI p-value
Male/female 0.73 0.35–1.5 0.39
Age at transplantation (per year) 1.05 1.02–1.09 0.004
Pre-emptive transplantation (no dialysis) 0.24 0.09–0.64 0.004
Cardiovascular disease prior to transplantation 3.18 1.55–6.52 0.002
Log C-reactive protein (mg/ml) 2.51 1.26–4.98 0.009
Naive CD4 T cells (per cell/ul) 0.99 0.98–0.99 < 0.0001
Naïve CD8 T cells (per cell/ul) 0.98 0.97–0.99 0.001
CD4/CD8 ratio 0.57 0.38–0.86 0.007
CMV positive serostatus 1.41 0.66–3.10 0.36
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CD31+ naïve T cells are considered to be equivalent to
naïve T cells that have recently emigrated from the thy-
mus and/or have not undergone prior TCR-induced pro-
liferation. Although maybe not the perfect parameter, the
number of CD31+ naïve T cells could be considered as an
indicator of thymus function [23, 25]. With increasing age
the thymus involutes resulting in an almost linear de-
crease in CD31+ CD4+ naïve T cells [4, 26]. Specifically,
the circulating naïve CD8+ T cell subset shrinks substan-
tially [27] while the number of CD31− CD4+ naïve T cells
shows a compensatory increase [28]. This normal physio-
logical ageing process is also observed in patients with
chronic renal failure but their thymic output of naïve T
cells, either measured by CD31 expression or content of
TCR excision circles (TCR) [7, 26], shows premature bio-
logical ageing by 15–20 years. This premature ageing of
the thymus function was confirmed in this study and re-
cipients most affected by immunological ageing, showing
a severe decreased thymic output, appeared to have the
highest mortality rate after transplantation. Currently, it is
not known why some patients have such a low thymic
output but low levels of interleukin 7 in ESRD patients
may play a role [29]. A previous study showed that the de-
cline in naïve T cell numbers is associated with the pro-
gression of stage of renal insufficiency, indicative of a
causative role for eGFR loss [29]. It is well-documented
that patients with ESRD have a pro-inflammatory immune
status [30]. Related to this phenomenon, activation-
induced apoptosis of naïve T cells is higher in ESRD pa-
tients [4]. A shift from lymphoid to myeloid progenitor
stem cells in the bone marrow, induced by inflammation-
associated epigenetic changes, offers another possible ex-
planation [1]. However, currently there are no studies that
have tested these hypotheses in an experimental model.
The inter-individual variation of thymic output and de-
cline over time is substantial both in ESRD patients and
Table 4 Multivariate Cox regression analysis for outcome death after transplantation
Hazard ratio 95% CI p-value
Multivariate model with CD4/CD8 ratio
Male sex 0.36 0.16–0.78 0.011
Age at transplantation (per year) 1.07 1.03–1.11 <.001
Pre-emptive transplantation (no dialysis) 0.25 0.09–0.70 0.008
Cardiovascular disease prior to transplantation 2.19 0.92–4.45 0.08
Log C-reactive protein (mg/ml) 1.82 0.83–3.97 0.134
CD4/CD8 ratio 0.57 0.37–0.86 0.008
Multivariate model with CMV serostatus
Male sex 0.40 0.18–0.86 0.02
Age at transplantation (per year) 1.06 1.02–1.1 0.001
Pre-emptive transplantation (no dialysis) 0.26 0.10–0.74 0.010
Cardiovascular disease prior to transplantation 1.76 0.81–3.81 0.152
Log C-reactive protein (mg/ml) 2.11 0.96–4.66 0.064
CMV positive serostatus 1.14 0.53–2.46 0.73
Multivariate model with naïve CD4 T cells
Male sex 0.29 0.28–0.66 0.036
Age at transplantation (per year) 1.06 1.02–1.09 0.002
Pre-emptive transplantation 0.25 0.09–0.68 0.006
Cardiovascular disease prior to transplantation 1.57 0.70–3.50 0.27
Log C-reactive protein (mg/ml) 1.81 0.83–4.84 0.036
Naive CD4 T cells (per cell/ul) 0.99 0.98–0.99 < 0.001
Multivariate model with naïve CD8 T cells
Male sex 0.42 0.19–0.92 0.030
Age at transplantation (per year) 1.04 0.99–1.07 0.056
Pre-emptive transplantation 0.26 0.09–0.68 0.005
Cardiovascular disease prior to transplantation 1.61 0.77–3.48 0.22
Log C-reactive protein (mg/ml) 2.09 1.01–4.33 0.115
Naive CD8 T cells (per cell/ul) 0.98 0.96–0.99 0.006
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healthy individuals and ageing is the most prominent fac-
tor influencing this process. A positive CMV serostatus is
associated with a (modest) decrease in numbers of naïve T
cells but was not a confounding factor in this study.
The observation of a lack in compensatory increase of
CD31− naïve T cells in the deceased recipient group is
intriguing but cannot be readily explained. In previous
studies, an increased susceptibility for activation-induced
cell death was identified as possible contributor to naïve
T cell lymphopenia in ESRD patients [4, 9]. Although
speculative, increased activation-induced cell death may
be more prominently present in the deceased recipient
group, e.g. because of a greater degree of systemic in-
flammation. As a general marker of systemic inflamma-
tion the serum C-reactive protein concentrations were
measured at time of T cell analysis but showed no rela-
tion with naïve T cell numbers (data not shown). How-
ever, in a recent study by Chiu et al. a significant
correlation was observed between naïve CD8 T cell
numbers and serum CRP level [8]. In that study virtually
all patients were CMV seropositive which may indicate
that CMV, by causing increased systemic inflammation
[31, 32], could induce naïve T cell depletion.
In ESRD patients, the reintroduction of adequate renal
function by successful renal transplantation leads to a
rapid normalization of uremia-associated inflammation
and oxidative stress [33, 34]. These processes are thought
to underlie the impact of renal failure on the immune sys-
tem but their reversal does not lead to a change of T cell
ageing parameters [35]. However, we could not show a
relation between early post-transplantation infection risk
and e.g. low numbers of naïve T cells [36]. In the current
study, the thymic output in both the deceased and living
group of recipients remained remarkably stable, indicating
that even the most severely affected patients do not even
partially restore their thymic function.
In a previous study, it was shown that the number of
circulating naïve T cells closely correlates with the con-
tent of naïve T cells in the lymph nodes [37]. Therefore,
redistribution of naïve T cells to the lymphoid tissue
does not seem likely. However, it has recently become
clear that naïve T cells may be compartmentalized early
in life and can reside in many non-lymphoid tissues [38,
39]. Whether all these naïve T cell populations in tissues
are similarly affected by renal failure is not known.
The low thymic output may be directly related to an
increased mortality, e.g. by a decreased immune re-
sponse to new pathogens, or may act as a sensitive bio-
marker for an aged biological (immune) system. This is
a highly relevant question as when the latter assumption
holds true, rejuvenation of thymic function alone may
not be sufficient to decrease mortality risk.
The number of naïve T cells in elderly individuals has
been linked to frailty and mortality [40, 41] although this
was not found in all studies [42]. With regard to recipi-
ents of a renal transplantation low numbers of CD4+ T
cells are associated with cardiovascular mortality [43]
and opportunistic infection with Pneumocystis jiroveci
pneumonia after transplantation [44]. In the latter study,
it was noted that the lymphopenia was a relatively stable
Fig. 3 Dynamics of naïve T cells post-transplantation. The longitudinal course of total CD4+ (A) and CD8+ (C) naïve T cell numbers and the CD31-
expressing subset of naïve CD4+ T cells after renal transplantation are shown. On the x-axis the time of sampling is shown: before transplantation
(0) and the months after transplantation (3, 6, 12). Cell numbers are given in means with standard error of the mean forrecipients alive (green
dots) and deceased recipients at the time of follow-up (red dots)
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feature of the patients involved, confirming our observa-
tion that ESRD-related lymphopenia is not affected by
renal transplantation. The current data, in accordance
with previous studies, shows that ESRD-related lympho-
penia is largely due to a loss of circulating naïve T cells.
Therefore, the results of the above mentioned studies
are most likely explained by the naïve CD4+ T cell lym-
phopenia which is underlying the total CD4+ T cell lym-
phopenia. In addition, the lower CD4+ T cell count in
the deceased recipients groups lowers the CD4/CD8 T-
cell ratio which is therefore significantly associated with
all-cause mortality. This is in accordance with the results
of previous studies in healthy adults [45]. CMV-
seropositivity is a potential strong confounder of this as-
sociation because of the CMV-infection associated
increase in the CD8 T cells count [22] leading to a sig-
nificantly decreased CD4/CD8 T-cell ratio. As the fre-
quency of CMV seropositivity increases with age and is
negatively related to socio-economic status, the CD4/
CD8 T-cell ratio as biomarker for mortality risk is highly
susceptible for misinterpretation [30].
There are some obvious limitations to the current
study that are worth mentioning. Our cohort of kidney
transplant recipients all received a kidney of a living
donor. This lead to a very homogenous cohort of recipi-
ents, not receiving T cell depletion therapy, almost no
delayed graft function and excellent one-year patient
and graft survival. In other transplantation programs,
the majority of kidneys are from deceased donors and T
cell depletion is regularly given as induction therapy.
Therefore, the generalizability of the current findings is
unknown at present. Another limitation is the relative
low numbers of events (recipients deceased at follow up)
limiting extensive multivariate analysis and allowing for
confounders not identified.
Conclusions
A severely lowered number of circulating naïve T cells, indi-
cative of a very low thymic output, before renal transplant-
ation is not reversed by renal transplantation per se and is
strongly associated with long term all-cause mortality.
Methods
Study population
All ESRD patients who received a kidney from a living-
donor in the period from November 1st 2010 to October
1st 2013 were considered for participation. Follow-up of
patients included in the study was until November 2018.
All patients received a similar immunosuppressive
regimen. This included induction therapy with basilixi-
mab (Simulect®, Novartis) and maintenance therapy with
tacrolimus (Prograf®, Astellas Pharma), mycophenolate
mofetil (Cellcept®, Roche), and glucocorticoids. Clinical
variables were assessed as shown in Table 1, including
age, gender, CMV-seropositivity, number of prior renal
transplantations, underlying cause of renal failure, pre-
emptive RT. The primary end-point of the study was all-
cause mortality. Cause of mortality was documented as
either cardiovascular disease, cancer, infectious disease,
other and unknown. HLA-typing was performed accord-
ing to the international standards (American Society for
Histocompatibility and Immunogenetics/the European
Federation for Immunogenetics) using serologic and
DNA-based techniques. PRAs were determined at the la-
boratory of the blood bank in Leiden, the Netherlands.
PBMC isolation
By using Ficoll-Paque Plus (GE healthcare, Uppsala,
Sweden), peripheral blood mononuclear cells (PBMC)
were isolated from heparinized blood samples. Blood was
drawn from RT-recipients the day before RT, and at 3, 6
and 12months after RT. Isolated PBMCs were stored at
-150°C with a minimum amount of 10 × 106 cells per vial.
T cell differentiation status and absolute numbers of T
cell subsets
To determine the T-cell differentiation status a whole
blood staining was performed based upon a study by Sal-
lusto et al. [46] as described in detail previously [4]. Naïve
T cells were defined by the expression on either CD4 or
CD8, CCR7 and the absence of CD45RO. Absolute num-
bers of the different T cell subsets were determined via a
Trucount staining as described by Bouvy et al. [47].
Statistics
The difference between continuous variables was assessed
with the Mann–Whitney U test. Normal distribution of data
was assessed by the Shapiro-Wilk test of normality. Not-
normal distributed data were represented in medians with
interquartile range. The difference between categorical vari-
ables was analyzed either with the Pearson’s chi-squared test
or with the Fisher’s exact test depending on the expected
values in any of the cells of a contingency table. Cox propor-
tional hazard analysis was used to assess the association be-
tween immunological parameters and the outcome all-cause
death, including relevant clinical parameters (age, sex, pre-
emptive transplantation, cardiovascular disease, C-reactive
protein) in the model. Univariate Cox proportional hazards
analysis was used to identify clinical and demographic vari-
ables associated with death at follow-up. Variables with a p-
value of ≤ 0.1 and sexe were considered for further analysis
by multivariate logistic regression to calculate hazard ratios
and corresponding confidence intervals. PH assumption of
variables were tested by visual inspection of log-minuslog
graphs and further tested by assessment of time-
dependency using the Cox regression with time-dependent
covariate module in SPSS. All variables met the demands of
PH unless stated otherwise. Interaction terms that met
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statistical significance (p < 0.05) were included in the multi-
variate model. Correlation matrices were made for the as-
sessment of significant correlations. Absence of collinearity
in the model covariates was formally assessed by calculating
the variance inflation factor.
The significance level (p-value) was two-tailed and an
α of 0.05 was used for all analyses. Statistical analyses
were performed using SPSS® version 21.0 for Windows®
(SPSS Inc., IL, USA) and GraphPad Prism 5 (CA, USA).
Figures were created with GraphPad Prism 5 (CA, USA).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12979-020-00175-z.
Additional file 1: Table S1. Naïve T cell numbers before
transplantation in recipients stratified for CMV serostatus and survival
after transplantation.
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